恒瑞医疗自主研发的“均一粒径载药微球”核心技术获专利授权确认

Group 1 - The core technology of "uniform particle size drug-loaded microspheres" developed by Suzhou Heng Rui Medical Devices Co., Ltd. has received patent authorization from the United States Patent and Trademark Office (USPTO) [1] - Liver cancer ranks sixth in incidence and third in mortality globally, with approximately 72% of cases occurring in Asia, particularly in China, which accounts for about 50% of global cases [1] - The early diagnosis rate for liver cancer is less than 30%, and the five-year survival rate for patients in mid to late stages is only 12%, with a postoperative recurrence rate as high as 50%-70% [1] Group 2 - The Ministry of Industry and Information Technology's "14th Five-Year Plan for the Development of the Medical Equipment Industry" emphasizes the localization of high-end interventional devices, aiming for domestic medical device performance to reach international standards by 2025 [2] - The patent authorization represents a significant response to national medical device strategies, primarily benefiting domestic liver cancer patients in need of better treatment options [2] - Heng Rui Medical's breakthrough technology is expected to lower the treatment threshold for D-TACE, facilitating its widespread application in domestic hospitals and reducing the need for patients to seek expensive imported materials [2] Group 3 - The core value of the patent authorization lies in overcoming the global challenge of "particle size uniformity" in drug-loaded microspheres, establishing a new global precision standard based on Chinese standards [2] - Heng Rui Medical aims to leverage this patent authorization to deepen its focus on the precision embolization field and accelerate the implementation of domestic innovative results in clinical settings [2] - The company seeks to transform cutting-edge technology into accessible treatment options for Chinese patients while providing superior "Chinese solutions" for global cancer patients [2]